Clinical Trial

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 1, 2024 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial aims to find the MTD of Venetoclax when added to Fludarabin, Amsacrine and Ara-C + Treosulfan and to evaluate whether the addition of Venetoclax to sequential conditioning with FLAMSA + Treosulfan is safe for allogeneic blood stem cell transplantation in patients with high-risk MDS, CMML or sAML (FLAMSAClax)
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-03-29; most recent amendment 2024-04-30.
Status change: Not Yet Recruiting → Recruiting 2023-06-29
Trial Details
NCT Number NCT05807932
Lead Sponsor Heinrich-Heine University, Duesseldorf
Collaborators: Koordinierungszentrum für Klinische Studien - Duesseldorf
Conditions Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Enrollment 38 participants
Start Date 2023-06-26
Primary Completion 2026-01-31 (estimated)
Study Completion 2028-01-30 (estimated)
Updated on ClinicalTrials.gov 2024-05-01